Ifosfamide
Ifosfamide is only found in individuals that have used or taken this drug. It is a positional isomer of cyclophosphamide which is active as an alkylating agent and an immunosuppressive agent. [PubChem]The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellliar molecliar structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA reslits in cell death.
Structure for HMDB15312 (Ifosfamide)
C7H15Cl2N2O2P
261.086
260.02481966
3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2λ⁵-oxazaphosphinan-2-one
ifosfamide
3778-73-2
HOMGKSMUEGBAAB-UHFFFAOYSA-N
This compound belongs to the class of chemical entities known as isofamides. These are oxazaphospholanes containing the isofamide skeleton. Isofamide is a heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.
Chemical entities
Organic compounds
Organoheterocyclic compounds
Oxazaphosphinanes
Isofamides
Aliphatic heteromonocyclic compounds
Expected but not Quantified
Solid
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-001i-0490000000-17ba12fd0e00df2723dcView in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-03di-0090000000-d4e1a660175509162e8cView in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-03di-0090000000-c26cb9c6b0b1cafbc7c2View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0gx3-6960000000-e4f4eadda4e355e7dd84View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0f6x-8900000000-10d5b2623785719eb1e7View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-9500000000-d06de43b506b64b21f31View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-9300000000-698d7a6ed4f1837ad721View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-03di-0090000000-084cc16ffb95bd0ef960View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-03di-0090000000-1ae1b6f01a6e1a37e34cView in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0gx3-6960000000-ad40c4b969e8d0286677View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0f6x-8900000000-137610f53c637d8d5b79View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-9500000000-6b78178980477a0f7c08View in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-0006-9200000000-e6f6b95f30fc4c9fde8aView in MoNA
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-001i-0490000000-661cabcd304902a3d4b5View in MoNA
LC-MS/MS Spectrum – , positivesplash10-001i-0290000000-4c400c6848932e5bc304View in MoNA
LC-MS/MS Spectrum – , positivesplash10-03di-1390000000-cb6bb34e3efac3f15b24View in MoNA
LC-MS/MS Spectrum – , positivesplash10-0udi-3910000000-2729bcf5701a78198ad5View in MoNA
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
1H NMR SpectrumNot Available
13C NMR SpectrumNot Available
Not Available
Not Available
None
None
DB01181
Not Available
Not Available
Not Available
Not Available
Not Available
3562
C07047
Not Available
Not Available
Ifosfamide
HMDB15312
HMDB15312
Not Available
3690
Not Available
5864
- Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
- Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep. 1976 Apr;60(4):451-8. [PubMed:1277221 ]
- Dechant KL, Brogden RN, Pilkington T, Faulds D: Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428-67. [PubMed:1720382 ]
- Schoenike SE, Dana WJ: Ifosfamide and mesna. Clin Pharm. 1990 Mar;9(3):179-91. [PubMed:2107997 ]
- Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66. [PubMed:3286879 ]
- Brade WP, Herdrich K, Varini M: Ifosfamide–pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1-47. [PubMed:3896483 ]
- Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994 Jun;26(6):439-56. [PubMed:8070218 ]
- Fleming RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S. [PubMed:9322882 ]
- Furlanut M, Franceschi L: Pharmacology of ifosfamide. Oncology. 2003;65 Suppl 2:2-6. [PubMed:14586139 ]
- Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. [PubMed:15827549 ]
- (). FDA label . .